Feasibility Study of the Aliya System in the Treatment of Early Stage Non-small Cell Lung Cancer

Inclusion Criteria:

* Presence of solitary NSCLC nodule 8th ed. stage IA2, IA3 or IB
* Nodule measuring \> 1 cm and ≤4 cm diameter by CT size estimate (e.g. T1b, T1c, T2a), with a minimum 1 cm solid component
* High pre-procedure probability of malignancy as determined by the investigator
* Patient has been evaluated by a thoracic surgeon and deemed a candidate for definitive lung tissue resection
* Patient is, in the opinion of the principal investigator, able to adhere to and undergo bronchoscopy, surgical procedure and post-treatment care

Exclusion Criteria:

* Additional pulmonary nodules requiring intervention
* Patient is receiving concurrent cancer treatment (e.g. external beam radiation therapy, brachytherapy, chemotherapy, targeted therapy, immunotherapy, other focal therapy) or has received treatment for the index tumor in the last two years
* Patient has implanted lung devices or electronic devices
* Patient has N1 disease
* Patient is immune compromised or receiving immune modulating medication
* Recurrent NSCLC within 2 years of initial definitive treatment
* Previous checkpoint inhibitor treatment for another cancer